Ali MohamedVP, CMC at Immatics, USA
Ali Mohamed, PhD, VP of CMC, Immatics US Inc. in Houston TX leading the development and manufacturing of Adoptive Cell Therapies for various solid cancers in collaborations with University of Texas MD Anderson Cancer Center. Dr. Mohamed has nearly 20 years of experience in process development and GMP manufacturing of regenerative medicine, cell and gene therapy products at various CMOs and clinical stage companies. Before joining Immatics, Dr. Mohamed was the senior director of manufacturing operations/ manufacturing development at PCT (now HCATS) helping their clients manufacture cell & gene therapy products. Before joining PCT, Dr. Mohamed led the development of AlloCure’s MSCs for acute kidney injury and previous to that he helped Lonza clients develop various cell therapy products. Dr. Mohamed holds a PhD in Molecular Pharmacology from Medical College of Ohio and postdoctoral fellowship in neuroscience and neurobiology from the Georgetown University Institute of Cognitive and Computational Sciences (GICCS).